MGK2—
You suggested the piece was gonna be concise…
MGK2—
You suggested the piece was gonna be concise… so I read it.
680 words? To basically say what most of us already know? Coulda been done in half the words…
That’s the problem I have with most of your posts—and, apparently the posts you highlight—they gussy up what most of us on this board already know. And they are excessively wordy—which you alluded to in your introduction… so this wordy response is fair game, right?
You are talking to the converted… and most of us are very conversant/up-to-date with what’s going on with leronlimab. So the post might have been appropriate for newbies and those ignorant of leronlimab’s promise. But for this board—c’mon! Ya kinda belittle our awareness of the promise that this drug has…
Two specific problems I have with Tiny’s argument, and your highlighting the post:
In the comparison of leronlimab with Trodelvy, under Tumor Shrinkage we have “some complete responses; numbers coming at ESMO.” Under Complete Remissions we have “confirmed complete remissions; final count revealed at ESMO.” And for Median Survival we have “>50% alive at 12 months.” All promising… but when you base most of your argument on essentially “final numbers at ESMO,” well why not wait for ESMO? Aren’t you getting ahead of yourself? And we all know generalizing from incomplete evidence is worse than… incomplete evidence.
As far as the “real toxicity” that comes with Trodelvy,” well, 4 out of 10 coming down with neutropenia sounds pretty bad… Now I don’t have a medical degree… but let me decode my experience with chemo for you. I received oxaliplatin and capecitabine for Stage 3 locally advanced colon cancer in the spring/summer of 22 (after 10 inches of my lower colon was surgically removed). After three or four rounds of treatment I was told my bloodwork revealed neutropenia and was given a couple pre-filled syringes to shoot myself up with at home. Did a couple injections, more bloodwork. I was fine. No further problems. So the idea that neutropenia is “classic, brutal chemo” was certainly not my experience. And I wonder why Tiny highlighted neutropenia. I’d be more worried about the severe diarrhea… If it was anything like the glycol 3350 laxative I took for my colonoscopy-surgery, well, that was no fun even if it wasn’t unexpected or explosive!
So, I don’t want to make the same mistake as Tiny—generalizing from limited evidence. Maybe I should have been more worried about the neutropenia. (My oncologists didn’t make like it was a big deal… maybe he was being low-key just to spare me worry). But it certainly wasn’t brutal chemo. Perhaps some other medical professionals could weigh in?
Back in 22 I asked my oncologist about leronlimab… Of course he hadn’t heard about it. I would have taken it in a heartbeat! From all I’ve read since it would have been useful. Perhaps curative. The lack of serious adverse effects is one of leronlimabs greatest attributes…. Along with the promise of efficacy in both chronic and acute diseases. But we all know that!
No one is more bullish about leronlimab than yours truly. Bullish—I’m a fuckin Mastadon! But generalizing from incomplete evidence, and scaring people with chemo-fear… I really don’t get it. I trust the science. And we are not there yet. So close! And it’s hard to wait. Listen--I applaud Tiny’s and MGK2’s enthusiasm. But keep it in your pants. And don’t use science-talk to support unscientific conclusions. It is an insult to our collective intelligence. Even if it may make us feel good in the short run. And the danger in hyping this is not what we choose to believe about leronlimab—it’s what the medical pros believe. 45 minutes and a poster competing with some 400 other posters at a busy conference? I’ll wait for the CRC trial results and any further news about mTNBC before I wet myself. And when the share price begins to head north I'll let myself dream of the South Seas...
Of course any partnership news would rile me up too! And Pestell's conference talk in May could be the catalyst we have been waiting for. But at this point, anything less is just talk. And we all know... talk is cheap.
And MGK2—you have the research skills to really make a contribution. So stick with the science instead of the cheerleading.
—Sherlock—
25
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
From Add-on to Standalone: SlidesAI's Big Leap You know what they say: time waits for no one, and that seems true in tech too. Those suit-and-tie presentation days? SlidesAI just took a swing at redefining them. Once a trusty sidekick locked into Google Slides, it's now captaining its own ship. Welcome to the SlidesAI standalone presentation platform—where AI meets your...
Continue Reading
The air's thick with tension as Coastal Financial Corporation (NASDAQ:CCB) finds itself embroiled in a securities class action lawsuit. Investors who grabbed shares between October 28, 2024, and July 29, 2026, are in the spotlight and urging those with losses to make a move by the December 1, 2026, lead plaintiff deadline. Sounds like a real mess, doesn't it? Well, it's a...
Continue Reading
Synova and Eventus: A Powerful Partnership If you've ever traded a share or two, you know the name of the game is risk management. Step into Synova Global's latest move, and you'll see a gamble worth watching closely. This time around, Synova has tapped Eventus to bring their Validus trade surveillance platform into the fold. Now, Eventus and its star player, Validus,...
Continue Reading
Highway to Earnings: RideNow's Third Quarter Call Alright, folks, this is the moment the powersports crowd has been itching for. RideNow Group, Inc. (NASDAQ: RDNW) is set to roll out their third-quarter financial results on November 10, 2026. If you're in for a wild ride—pun fully intended—mark this on your calendars. With this company hogging the spotlight in the...
Continue Reading
The Quiet Revolution: Linux Takes Center Stage Linux, once the underdog of operating systems, is gaining significant traction in the world of AI development. It's not just a nerd's sandbox anymore; it's rapidly becoming the go-to platform for cutting-edge AI innovation. Now, more enterprise IT departments are facing the choice of keeping up with Linux's popularity—or...
Continue Reading
The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...
Continue Reading
When Hotels Stand Up for Heroes Every now and then, you stumble upon a company doing something genuinely good, and Staypineapple's effort this November is one of those rare gems. In honor of Veterans Day, they're opening their checkbook to sling some real support to our nation’s vets and retired first responders. Their chosen cause? The American Humane Society's...
Continue Reading
A Dividend Declaration with a Side of Mergers Viatris, the healthcare giant operating on a global scale, has been making some noise recently. On the surface, it's another quarterly dividend—$0.12 per share, set to hit the pockets of shareholders on December 16. But there's a lot more cooking under the hood of this announcement that ticks just about every box for a...
Continue Reading
What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...
Continue Reading
WuXi Strikes Gold with ESG Distinction Take a look under the hood, and you’ll find that WuXi Biologics (2269.HK) isn’t just playing the long game—they’re redefining it. They’ve clinched not one, but two prestigious honors from the Hong Kong ESG Reporting Awards (HERA). And with sustainability in the hot seat worldwide, these wins are no small potatoes. They...
Continue Reading
Top 5 Most Recently Viewed Articles
Encore Wound Care Recognized Among America's Fastest-Growing Companies Encore Achieves New Heights with Impressive Revenue Growth Encore Wound Care has made a remarkable entrance onto the Inc. 5000 list, showcasing its impressive three-year revenue growth of 6,745%. This accolade places Encore at No. 32 overall, while also ranking it No. 2 within its home state and No. 9...
Continue Reading
Magyar Bancorp's Prestigious Recognition in Banking In a noteworthy achievement, Magyar Bancorp, Inc. (NASDAQ: MGYR), the parent company of Magyar Bank, has secured a position on the prestigious KBW Bank Honor Roll for 2025. This accolade highlights the remarkable performance of this institution within a select group of 16 elite banks, showcasing those that exhibit the...
Continue Reading
Class Action Lawsuit Against Open Lending Corporation Open Lending Corporation is currently facing serious allegations that have sparked interest among investors. Robbins LLP has come forward to inform all stockholders that a class action lawsuit has been initiated on behalf of those who purchased or acquired stocks during a specific period. This lawsuit has drawn...
Continue Reading
Breaking New Ground in Global Education Who would've thought that two schools outside the U.S. would be the first to snag the Cognia American School Certification? Yep, John F. Kennedy, The American School of Querétaro in Mexico, and Union School in Haiti have paved the way. This certification ain't just a sticker; it's about meeting a laundry list of rigorous...
Continue Reading
AstraZeneca Class Action Lawsuit: What Investors Need to Know Recent developments at AstraZeneca PLC (NASDAQ: AZN) show a significant opportunity for investors who purchased the pharmaceutical company's securities within a specific time frame. The Rosen Law Firm has initiated a class action lawsuit aimed at addressing securities fraud claims that impact numerous...
Continue Reading